CATALOGO DEI PRODOTTI DELLA RICERCA

BELLUOMINI, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.379
NA - Nord America 3.192
AS - Asia 2.732
SA - Sud America 389
AF - Africa 130
OC - Oceania 19
Totale 9.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.073
RU - Federazione Russa 1.742
SG - Singapore 1.257
IT - Italia 512
CN - Cina 445
HK - Hong Kong 304
BR - Brasile 303
VN - Vietnam 277
DE - Germania 258
FI - Finlandia 151
GB - Regno Unito 134
FR - Francia 125
SE - Svezia 95
IN - India 91
KR - Corea 89
IE - Irlanda 79
CA - Canada 72
PL - Polonia 72
NL - Olanda 64
ID - Indonesia 42
JP - Giappone 42
ES - Italia 32
TR - Turchia 30
AR - Argentina 27
TG - Togo 27
MX - Messico 26
BJ - Benin 25
BD - Bangladesh 23
AT - Austria 21
CZ - Repubblica Ceca 20
NG - Nigeria 20
ZA - Sudafrica 17
AU - Australia 16
EC - Ecuador 15
UA - Ucraina 14
VE - Venezuela 14
IQ - Iraq 13
CO - Colombia 12
PK - Pakistan 12
JO - Giordania 11
MA - Marocco 11
IR - Iran 10
MY - Malesia 10
BE - Belgio 8
CH - Svizzera 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
LT - Lituania 7
SA - Arabia Saudita 7
TW - Taiwan 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
CL - Cile 6
DK - Danimarca 5
KE - Kenya 5
KZ - Kazakistan 5
UY - Uruguay 5
AO - Angola 4
CR - Costa Rica 4
CY - Cipro 4
DZ - Algeria 4
IL - Israele 4
PT - Portogallo 4
TN - Tunisia 4
AM - Armenia 3
BO - Bolivia 3
HN - Honduras 3
JM - Giamaica 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
PY - Paraguay 3
RS - Serbia 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
AL - Albania 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
GD - Grenada 1
HU - Ungheria 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MG - Madagascar 1
Totale 9.832
Salva come PNG Salva come JPEG
Città #
Singapore 671
Moscow 617
Dallas 542
Ashburn 540
San Jose 441
Hong Kong 290
Verona 169
Chandler 155
Munich 154
The Dalles 122
Los Angeles 102
Ho Chi Minh City 87
Beijing 83
Helsinki 83
Council Bluffs 77
Dublin 77
New York 76
Hanoi 56
Milan 55
London 48
São Paulo 43
Buffalo 38
Meda 38
Tokyo 38
Redondo Beach 36
Warsaw 32
Lappeenranta 28
Turku 28
Lomé 27
Orem 27
Santa Clara 27
Chicago 26
Montreal 26
Cotonou 25
Rome 24
Amsterdam 23
Jakarta 23
Nuremberg 23
Redmond 21
Lawrence 20
Princeton 20
Toronto 20
Da Nang 19
Frankfurt am Main 19
Abuja 18
Chennai 18
Columbus 18
Houston 18
Sindelfingen 18
Atlanta 17
Brooklyn 17
Seoul 17
Denver 16
Boardman 15
Haiphong 15
Stockholm 15
Johannesburg 14
Mumbai 14
Phoenix 14
Seattle 14
Washington 14
Boston 13
San Francisco 13
Barnet 12
Belo Horizonte 12
Naples 12
New Delhi 11
Amman 10
Bologna 10
Brno 10
Falkenstein 10
Istanbul 10
Tianjin 10
Vienna 10
Wilmington 10
Biên Hòa 9
Hyderabad 9
Jacksonville 9
Paris 9
Rio de Janeiro 9
Shanghai 9
Sydney 9
Vicenza 9
Brussels 8
Bursa 8
City of London 8
Kyiv 8
Manchester 8
Ottawa 8
Poplar 8
Porto Alegre 8
Querétaro 8
Trento 8
Turin 8
Bengaluru 7
Chapel Hill 7
Charlotte 7
Guangzhou 7
Kuala Lumpur 7
Madrid 7
Totale 5.723
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 307
Exploring the Complex Interplay between Myeloid-Derived Suppressor Cells (MDSCs), Interleukins, and Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC) 298
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 187
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 186
A multimodal approach to cancer-related cachexia: from theory to practice 185
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 175
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 174
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 174
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 162
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 162
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 161
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 158
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 156
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 154
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 151
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 151
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 150
A cross-sectional study exploring the perception of exercise oncology in the Italian population 150
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 146
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 141
Exercise and anemia in cancer patients: could make the difference? 140
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 138
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 136
Exercise oncology: It is time to make a change 135
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 134
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 131
Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer 130
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 129
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 128
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation 126
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 126
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study 122
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 122
Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials 121
Cross-sectional survey evaluating the psychological impact of the COVID-19 vaccination campaign in patients with cancer: The VACCINATE study 121
Exercise and bone health in cancer: enemy or ally? 119
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 119
Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it 115
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 115
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 114
Combining a 9-month tailored physical exercise program with osimertinib and denosumab in a patient affected by advanced NSCLC with multiple osteolytic bone lesions: A case report 114
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 112
Exploring the role of respiratory microbiome in lung cancer: A systematic review 111
Exercise in men with prostate cancer: how to move on? 110
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 108
Physical activity guidelines in oncology: a systematic review of the current recommendations 107
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective 107
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 107
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 107
Drive the oncologists into exercise promotion in lung cancer 102
The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents 101
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas 100
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction 100
HER2 Aberrations in NSCLC: So Close Yet So Far 98
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 98
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs 96
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 93
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures 91
What is the role of physical exercise in the era of cancer prehabilitation? A systematic review 90
Cardiac autonomic dysfunction in patients with cancer: exploring the role of physical exercise 90
Overcome the Fear of Exercise in Patients With Bone Metastases: A Qualitative Study on Patients' Perception 90
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy 89
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 87
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer 85
Willingness, preferences, barriers, and facilitators of a multimodal supportive care intervention including exercise, nutritional and psychological approach in patients with cancer: a cross-sectional study 84
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab 82
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 80
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors 74
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates 72
Effect of exercise on bone-related outcomes in patients with cancer affected by bone metastases or bone loss: a systematic review and meta-analysis 70
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk 70
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 69
Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer 69
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC 66
How a physical exercise program performed by patients may impact caregiver burden in cancer: a qualitative study 64
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 59
Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is Coming 59
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 51
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 50
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 49
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer 46
Lung Cancer Screening: An Opportunity to Promote Physical Activity? 45
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance 41
Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report 39
Telehealth-delivered exercise and nutrition intervention to improve outcomes in patients with early stage non-small cell lung cancer: protocol for the multicentre STARLighT phase II (neoadjuvant) and phase III (adjuvant) trial 34
Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib 32
Uncovering common transcriptional features shared by mature peripheral blood PMN-MDSCs and tumor-infiltrating neutrophils in humans 31
Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial 20
Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay 14
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity 9
Totale 9.970
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.450
article - articoli 33.877
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 573
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.900
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 16 9 0
2021/2022180 7 23 0 9 7 10 7 16 12 6 20 63
2022/2023463 22 50 40 93 26 111 1 25 49 12 25 9
2023/2024630 14 25 59 55 57 76 62 36 36 64 91 55
2024/20252.178 99 78 89 367 65 103 147 124 337 162 213 394
2025/20266.447 337 362 612 1.139 1.653 395 600 364 551 434 0 0
Totale 9.970